BioAtla, Inc.
BCAB- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826892
No open-market purchases or sales by BioAtla, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.22M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding BioAtla, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 81 | 87 | +6 |
| Shares | 32.7M | 32.0M | −710.0K (−2.2%) |
| Value | $87.6M | $96.1M | +$8.45M (+9.6%) |
New holders (25)
Institutions that held BioAtla, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
Sold out (19)
Institutions that held BioAtla, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Candriam Luxembourg S.C.A. | 1,565,406 | $3.86M |
| Avidity Partners Management LP | 602,500 | $1.61M |
| Wellington Management Group LLP | 365,228 | $978.8K |
| Laurion Capital Management LP | 292,600 | $784.2K |
| Marshall Wace, LLP | 285,661 | $765.6K |
| Susquehanna Fundamental Investments, LLC | 107,796 | $288.9K |
| Acadian Asset Management LLC | 92,683 | $247.0K |
| Caas Capital Management LP | 80,097 | $214.7K |
| Atom Investors LP | 55,476 | $148.7K |
| Jump Financial, LLC | 46,800 | $125.4K |
| Alps Advisors Inc | 31,115 | $83.4K |
| Occudo Quantitative Strategies LP | 21,719 | $58.2K |
| Squarepoint Ops LLC | 19,179 | $51.4K |
| Qube Research & Technologies Ltd | 18,710 | $50.1K |
| Diametric Capital, LP | 16,298 | $43.7K |
| Virtu Financial LLC | 10,302 | $28.0K |
| Quantbot Technologies LP | 4,851 | $13.0K |
| Simplex Trading, LLC | 1,858 | $4.00K |
| Crewe Advisors LLC | 345 | $925 |